Biogen Inc. stock outperforms competitors on strong trading day
Shares of Biogen Inc. BIIB rallied 2.60% to $140.64 Friday, on what proved to be an all-around grim trading session for the ...
Gene Therapy Market to Hit USD 36.55 Billion by 2032 with 19.4% CAGR | MarketsandMarkets™.
The global Gene Therapy market, valued at US$7.21 billion in 2023, is forecasted to grow at a robust CAGR of 19.4%, reaching ...
Hosted on MSN1d
Biogen Stock Is Mutating Into a Value Play
Biogen Inc. (NASDAQ: BIIB) has steadily declined since peaking at $468.55 in 2021, as shares are trading down 70.64% from ...
precisionmedicineonline2d
Biogen Inks Deal to Commercialize Stoke Therapeutics' Dravet Syndrome ASO; Stoke Retains US Rights
Biogen will receive rights to commercialize zorevunersen outside the US, Canada, and Mexico, paying $165 million upfront and other milestone payments.
Contract Pharma2d
Biogen, Stoke Partner on Zorevunersen in Dravet Syndrome
Biogen receives exclusive rights to commercialize zorevunersen outside U.S., Europe, and Japan.
Biogen Bets Up to $550 Million for Rights to Epilepsy Drug
Biogen Inc. has agreed to pay as much as $550 million to develop and sell a drug to treat a genetic seizure disorder, the ...
Chardan Capital Sticks to Their Buy Rating for Stoke Therapeutics (STOK)
In a report released today, Rudy Li from Chardan Capital reiterated a Buy rating on Stoke Therapeutics (STOK – Research Report), with a price ...
Global Alzheimer’s Platform Foundation Announces Strategic Collaboration with Roche for the Transformative Bio-Hermes-002 Study
Like Bio-Hermes-001, the Bio-Hermes-002 study is paving the way for improving participation by trial participants who are traditionally underrepresented in Alzheimer’s clinical research, with an ...
Multiple System Atrophy Market Set to Experience Significant Growth with Breakthrough Therapies by 2034 | DelveInsight
Multiple system atrophy (MSA) is a rare neurological disorder that leads to the progressive deterioration of nerve cells in ...